Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study

BACKGROUND AND PURPOSE: The KEYNOTE-181 study demonstrated that pembrolizumab for advanced or metastatic esophageal cancer in patients with programmed death ligand-1 (PD-L1) combined positive score (CPS) ≥ 10 had a survival advantage and better tolerability than chemotherapy. However, at the same ti...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhan, Mei, Xu, Ting, Zheng, Hanrui, He, Zhiyao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924414/
https://www.ncbi.nlm.nih.gov/pubmed/35309225
http://dx.doi.org/10.3389/fpubh.2022.790225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924414/
https://www.ncbi.nlm.nih.gov/pubmed/35309225
http://dx.doi.org/10.3389/fpubh.2022.790225

Ejemplares similares